{"id":"dpi-386-nasal-gel","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPI-386 represents a drug repurposing strategy by Repurposed Therapeutics, reformulated as a nasal gel to improve bioavailability and patient convenience through the intranasal route. The nasal delivery pathway allows for direct absorption across the nasal mucosa, potentially bypassing first-pass hepatic metabolism and enabling lower systemic doses. The specific molecular mechanism depends on the active pharmaceutical ingredient being repurposed, which is not publicly detailed in available sources.","oneSentence":"DPI-386 is a repurposed therapeutic delivered as a nasal gel formulation, designed to provide local or systemic therapeutic effects through intranasal administration.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:00.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05886660","phase":"PHASE2","title":"Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","status":"RECRUITING","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2022-01-21","conditions":"Motion Sickness, Space, Motion Sickness, Sea Sickness","enrollment":30},{"nctId":"NCT05852730","phase":"PHASE2","title":"Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","status":"RECRUITING","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2021-08-10","conditions":"Motion Sickness, Space, Motion Simulation, Parabolic Flight","enrollment":80},{"nctId":"NCT03988530","phase":"PHASE3","title":"Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-07","conditions":"Motion Sickness","enrollment":98},{"nctId":"NCT05548270","phase":"PHASE3","title":"Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2022-08-23","conditions":"Motion Sickness","enrollment":503},{"nctId":"NCT04947423","phase":"PHASE3","title":"Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2021-06-14","conditions":"Motion Sickness","enrollment":140},{"nctId":"NCT04272255","phase":"PHASE3","title":"Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness","status":"UNKNOWN","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-04-22","conditions":"Motion Sickness","enrollment":300},{"nctId":"NCT04219982","phase":"PHASE2, PHASE3","title":"DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness","status":"TERMINATED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2018-06-29","conditions":"Motion Sickness","enrollment":23},{"nctId":"NCT03986905","phase":"PHASE3","title":"The Prevention and Treatment of Nausea Associated With Motion Sickness","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-04-26","conditions":"Motion Sickness","enrollment":300},{"nctId":"NCT04184115","phase":"PHASE3","title":"Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-09","conditions":"Motion Sickness","enrollment":102},{"nctId":"NCT03920644","phase":"PHASE3","title":"Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels","status":"UNKNOWN","sponsor":"Naval Aeromedical Research Unit, Dayton","startDate":"2019-04","conditions":"Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":112,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["scopolamine","Transderm Scop®"],"phase":"phase_3","status":"active","brandName":"DPI-386 Nasal Gel","genericName":"DPI-386 Nasal Gel","companyName":"Repurposed Therapeutics, Inc.","companyId":"repurposed-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}